Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Juvenile dermatomyositis (JDM), the most common pediatric inflammatory myopathy, is associated with significant morbidity despite therapeutic advances. Distinct clinical phenotypes have emerged, which can correlate with myositis-specific antibodies. Because translational data solidify the role of type I IFNs in JDM disease pathogenesis, integration of clinical and molecular phenotyping may impact the choice of targeted therapy. This paper reviews clinical and molecular phenotyping in JDM and translational insights into immune pathogenesis that have created emerging options for targeted therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jid.2024.09.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Banker Type of Juvenile Dermatomyositis.
Indian J Dermatol
September 2025
Department of Dermatology, Krishnanagar Institute of Medical Sciences, Krisnanahgar, Nadia, West Bengal, India E-mail:
Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype.
Ann Rheum Dis
September 2025
Department of Pediatrics, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.
Objectives: Juvenile dermatomyositis (JDM) is a heterogeneous autoimmune condition needing targeted treatment approaches and improved understanding of molecular mechanisms driving clinical phenotypes. We utilised exploratory proteomics from a longitudinal North American cohort of patients with new-onset JDM to identify biological pathways at disease onset and follow-up, tissue-specific disease activity, and myositis-specific autoantibody (MSA) status.
Methods: We measured 3072 plasma proteins (Olink panel) in 56 patients with JDM within 12 weeks of starting treatment (from the Childhood Arthritis and Rheumatology Research Alliance Registry and 3 additional sites) and 8 paediatric controls.
Scleroderma renal crisis with overlap to dermatomyositis triggered by COVID-19 infection: a case report.
Mod Rheumatol Case Rep
September 2025
Department of Rheumatology, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura-shi, Kanagawa, 247-8533, Japan.
A 46-year-old man was diagnosed with anti jo-1 antibody-positive dermatomyositis 11 years ago and had been treated with prednisolone and tacrolimus. In the present case, after contracting SARS CoV2 virus infection, his dyspnea rapidly worsened, and he presented with renal and cardiac failure. Based on the biopsy results of the same area and anti-U1-RNP antibody positivity, he was diagnosed with systemic sclerosis and scleroderma renal crisis and required hemodialysis.
View Article and Find Full Text PDFUlcerative heliotrope rash in anti-MDA5-positive dermatomyositis.
Rheumatology (Oxford)
September 2025
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Divergence in Estimated Risks and Actual Rates of Atherosclerotic Cardiovascular Events and their Management in a Longitudinal Cohort of Patients with Dermatomyositis with Skin Involvement.
JID Innov
November 2025
Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Patients with dermatomyositis (DM), an autoimmune disorder affecting the skin, muscle, and lung, have been reported to be at a heightened risk of clinical events, chiefly heart attacks and strokes, from atherosclerotic cardiovascular disease. In this study, we examined current cardiovascular management in a single-center study of all 388 patients who have DM with skin involvement, either with symptomatic muscle disease ("classic DM") or with clinically amyopathic DM. By the new guidelines, the most recent low-density lipoprotein cholesterol levels were above goal for 290 of 388 (74.
View Article and Find Full Text PDF